Elanco Animal Health Inc (ELAN) research

Elanco Animal Health Inc
ShareXLinkedInReddit
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$22.93
As of

Elanco Animal Health Inc (ELAN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.

As of . Source: SEC EDGAR filings for ELAN. Method and limitations.

SHARE THIS CARD

Share the ELAN intelligence card

A branded snapshot of ELAN: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ELAN intelligence card preview
Post to X
LIVE TERMINAL

See ELAN live in the terminal

Track ELAN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ELAN terminal, free

Active signals for ELAN

FREE, NO ACCOUNT

Every signal on ELAN, as it fires

You are seeing 5 of 18 signals recorded on ELAN since 2026-06-10.

The five above landed across 2 days. The other 13 were recorded on 4 other days. 11 of the 18 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ELAN (2026Q2)

Manager / securityMarket value% portfolioQoQ
CITADEL ADVISORS LLCCUSIP 28414H103 · 2026Q2$237.9M0.03%,
MILLENNIUM MANAGEMENT LLCCUSIP 28414H103 · 2026Q2$67.1M0.02%,
D. E. Shaw & Co., Inc.CUSIP 28414H103 · 2026Q2$2.2M0.00%,
Bridgewater Associates, LPCUSIP 28414H103 · 2026Q2$2M0.01%,
TWO SIGMA INVESTMENTS, LPCUSIP 28414H103 · 2026Q2$311K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ELAN

ELAN against its peers

ELAN's net margin of -4.9% ranks in the 47th percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-05-31.

MetricELANPeer medianPercentilen
Revenue FY4.7B USD567M USD9716
Revenue YoYn/a-3.1%n/a6
Gross margin55.0%49.8%6813
Operating marginn/a2.0%n/a17
Net margin-4.9%-1.9%4717
Return on equity-3.5%-4.2%5014

Peers (18): KNSA, INDV, HLN, RGC, CURLF, HCM, PBH, ALVO, PRGO, ETON, GTBIF, HROW, CRON, TLRY, VREOF, AQST, EOLS, KMDA. Left out: RDY (period gap), SGIOF (no annual filing), HYPMY (no annual filing), GALDY (no annual filing), TAK (period gap), JHPCY (no annual filing), EVO (period gap). Fiscal periods ending between 2025-06-30 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (ELAN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ELAN signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ELANand get the insider, 13F, options, and confluence read in one view.

Open the live ELAN terminal, free